Streetbeat News

PRPO

Precipio, Inc.

https://www.precipiodx.com

Industry

Medical - Diagnostics & Research

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Precipio, Inc. (NASDAQ:PRPO) reported $0.3M cash generated from operations in Q2 2024, partly due to delayed cash collections from Q1. The company has $1.3M in cash reserves and is optimistic about reaching breakeven by year-end.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 1:09 pm

Precipio shares are trading higher after the company reported a Q2 revenue beat.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 6:45 pm

Precipio, Inc. (NASDAQ: PRPO) reported Q2 2024 revenue of $4.4M, surpassing the estimate of $4.33M. The company expects its Pathology Division's revenues to exceed $1.5M per month by year-end.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 1:21 pm

Precipio anticipates that its Pathology Division will return to exceeding its breakeven point in Q3-2024.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 1:04 pm

Precipio announced its FY23 revenue of $15.2M, marking a significant increase from the previous year's $9.4M.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 3:04 pm

Precipio shares were halted due to a circuit breaker triggered by an upside movement, with the stock currently up by 6.46%.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 3:04 pm

Precipio, Inc. (NASDAQ:PRPO) has signed a distribution agreement with Cardinal Health for its HemeScreen molecular assay products. This agreement allows Cardinal Health to market and distribute Precipio's HemeScreen portfolio to its extensive customer base, including hospital networks, reference laboratories, and physician-owned laboratories. This partnership is expected to strengthen Precipio's distribution network and position it for growth in 2024, alongside existing agreements with Fisher Healthcare and McKesson.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 3:00 pm

Precipio, Inc. (NASDAQ:PRPO) reported a significant reduction in its Cash Burn From Operations (CBFO) for Q4-2023, dropping below $100K, a more than 90% decrease from the previous quarter. The company's end-of-quarter cash balance decreased slightly from $1.5M to $1.4M. Despite this progress, management cautions that Q1-2024 may not show similar results due to seasonal declines in the pathology business and insurance payment delays. However, the Q4 results demonstrate Precipio's potential to reach cash flow breakeven and the company's confidence in its business model and market share growth.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 3:06 pm

Precipio, Inc. (NASDAQ:PRPO) has announced a 28% increase in Q3-2023 revenues to $4.5M, up from $3.5M in Q2-2023, and more than double the $2.2M from Q3-2022. The company attributes this growth to its pathology and products divisions, as well as efficiency and cost reduction initiatives. The company is approaching a $20M run rate and expects its operating cash flow to approach breakeven.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 1:07 pm

Precipio Inc has regained compliance with the Nasdaq Bid Price Rule, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 8:38 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.